<DOC>
	<DOCNO>NCT01168336</DOCNO>
	<brief_summary>The study aim evaluate safety pharmacokinetics extend release standard formulation betahistine administer monotherapy compare safety pharmacokinetics co-administered olanzapine determine potential dose limit toxicity and/or drug-drug interaction affect pharmacokinetics safety either medication , particular emphasis somnolence weight gain secondary olanzapine treatment</brief_summary>
	<brief_title>Evaluation Co-Administration Betahistine Adjunctive Olanzapine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Betahistine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Healthy subject 18 45 year age Body Mass Index ( BMI ) range 18.5 27.0 2 . Male female 3 . If female must nonlactating nonpregnant , measure negative urine pregnancy test , plan become pregnant study practice appropriate birth control oral contraceptive ( least 60 day ) , implant , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner , study duration 4 . Signed write informed consent . 5 . Willing able comply study procedure ( include report research center weekday evening administration stay overnight research facility require PK sampling 1 . Has know intolerance , sensitivity contraindication Betahistine Olanzapine , delineate product label 2 . Requires chronic need use systemic antihistamine , antiobesity agent psychoactive drug . 3 . Has significant body weight loss 4 kg 90 day prior screen . 4 . Has recently start smoke cessation program . 5 . Has screen ESS score 6 . 6 . Has personal history gestational diabetes , first degree relative diabetes . 7 . Has clinically significant abnormality screening , judge Investigator , laboratory test value ( chemistry , hematology , metabolic urinalysis ) , include Fasting blood glucose level 110 mg/dL HBA1c 6.0 % screening . Renal insufficiency define serum creatinine 1.5 mg/dL ( 133 Âµmol/L ) screening ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 ULN ; Triglycerides [ TG ] &gt; 200 mg/dL lowdensity lipoprotein cholesterol [ LDLC ] &gt; 190 mg/dL ) , Thyroidstimulating hormone ( TSH ) outside normal range ; 8 . Has clinically significant abnormality physical examination electrocardiogram ( ECG ) , judge Investigator 9 . Has clinically significant history presence disease unstable medical condition might affect enrollment trial , judge Investigator , include ; Cardiovascular cerebrovascular disease Diabetes mellitus ( type 1 2 ) ; Malignant disease within 5 year screen ; Polycystic ovary disease ; Hypertension ( sit blood pressure &gt; 140/90 mmHg screen randomization ) , History asthma symptom past 5 year ; History peptic ulcer past 5 year ; History HIV , Hepatitis B Hepatitis C 10 . Plans surgery ( elective otherwise ) course study ; 11 . Has receive investigational drug within 90 day prior screen . 12 . Has treat past 60 day , currently treat , expect require undergo treatment medication period 3 day ( exception antibiotic treatment period le 7 day ) . 13 . Is immediate family member personnel directly affiliate study investigative site , personally directly affiliate study investigative site ; employed OBEcure Ltd .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>betahistine olanzapine weight sleepiness</keyword>
	<keyword>olanzapine induce weight gain sleepiness</keyword>
</DOC>